---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-039882"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:35:10.300979+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zura Bio reports FY2023 net loss $60.4M, cash $99.8M, appoints Robert Lisicki as CEO

## Summary
- Net loss of $60.4M for FY2023 vs $25.7M in FY2022; R&D expenses $44.0M, G&A $18.6M.
- Cash and equivalents of $99.8M as of Dec 31, 2023, expected to fund operations into 2026.
- Founder and CEO Someit Sidhu steps down; President Robert Lisicki appointed CEO effective April 8, 2024.
- Sidhu remains on board as non-independent director; Board expands to ten members.
- Plans to initiate Phase 2 trial of tibulizumab (ZB-106) for systemic sclerosis in 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-039882
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/tm2410061d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-039882
- JSON: https://secwatch.observer/filing/0001104659-24-039882.json
- Plain text: https://secwatch.observer/filing/0001104659-24-039882.txt

## Key facts
- Earnings Releases
  Zura Bio Ltd reported financial results for full year 2023.
  - Period: full year 2023
  - Result: reported results
  source text: Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm
- Executive change
  Someit Sidhu changed role as Chief Executive Officer at Zura Bio Ltd.
  - Action: stepped down as CEO
  - Role: Chief Executive Officer
  source text: On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm
- Executive change
  Robert Lisicki was appointed as Director at Zura Bio Ltd.
  - Action: appointed
  - Role: Director
  source text: Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm
- Executive change
  Robert Lisicki changed role as Chief Executive Officer at Zura Bio Ltd.
  - Action: promoted
  - Role: Chief Executive Officer
  source text: Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924039882/0001104659-24-039882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.